Izervay (Avacincaptad Pegol) for AMD

Overview
Izervay is approved by the U.S. Food and Drug Administration (FDA) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Izervay is also known by its drug name, Avacincaptad Pegol.

Izervay is a complement inhibitor. It is believed to work by inhibiting the complement system, a part of the immune system that, when overactive, can contribute to the progression of AMD by damaging the retina.

How do I take it?
Prescribing information states that Izervay is administered by intravitreal injection (an injection into the eye), typically one per month (approximately every 28 days) for up to 12 months. Dosing amounts and schedules can vary from person to person, based on the assessment of the recommendation of the prescribing health care provider.

Adverse reactions
According to the drug’s prescribing label, the most common adverse reactions include conjunctival hemorrhage (bleeding in the eye), increased intraocular pressure (IOP), blurred vision, and neovascular AMD (new, abnormal blood vessel growth in the eye).

The label warns that intravitreal injections may be associated with endophthalmitis (inflammation inside the eye) and retinal detachments (when the retina pulls away from its normal position). 

For more information about this treatment, visit:

Label: Izervay — Avacincaptad Pegol Injection — DailyMed

Izervay — Drugs.com